Agenus Profile

USD 0.1  5.59%

Acquisition by Wadih Jordan of 3395 shares of Agenus subject to Rule 16b-3

Agenus insider trading alert for grant of deferred shares by Wadih Jordan, the corporate stakeholder, on August 4, 2018. This event was filed by Agenus Inc with SEC on 2007-07-03. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Agenus Summary

Agenus (AGEN) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 255 people. Agenus is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 188.24 M. Agenus conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 104 M outstanding shares of which 10.47 M shares are presently shorted by private and institutional investors with about 5.81 trading days to cover. ANTIGENICS INC currently holds about 52.35 M in cash with (119.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5.
Check Agenus Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 1.69HorizonTargetOdds Above 1.69
14.37%30 days 1.69 85.55%
Based on normal probability distribution, the odds of Agenus to move above current price in 30 days from now is about 85.55% (This Agenus probability density function shows the probability of Agenus Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Blackrock IncCommon Shares5.7 M13 M
Artal Group SaCommon Shares2.8 M6.2 M
Citadel Advisors LlcCall Options33.5 K76 K
Citigroup IncPut Options29.1 K66 K
View Agenus Diagnostics

Selected Agenus Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Agenus Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Agenus are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodys immune system to fight cancer. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 255 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Agenus SEC Filings
Agenus SEC Filings
Security & Exchange Commission EDGAR ReportsView All
ChairmanGaro ArmenView All
Thematic Classification
Currently Active Investing Idea
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
Business Address3 Forbes Road
ExchangeBATS Exchange
CIK Number0001098972
IndustryPharmaceutical Products
Phone781 674 4400
CurrencyUSD - US Dollar

Did you try this?

Run Pair Correlation Now

Pair Correlation

Compare performance and examine historical correlation between any two equity instruments
All  Next Launch Pair Correlation


Agenus Corporate Directors
Ulf Wiinberg Director
Shalini Sharp Director
Wadih Jordan Independent Director
Check also Trending Equities. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.